8-K: Scilex Sues Over $100M Collateral Fraud

Scilex Holding Company has filed a federal lawsuit seeking over $100 million in damages and recovery of 96 million shares, alleging unauthorized sale of collateral securities by multiple defendants including BNY Mellon.

Summary

• Scilex Holding Company filed a complaint in the U.S. District Court for the Central District of California against Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd. (collectively, the Wade Defendants), and The Bank of New York Mellon Corporation (BNY Mellon).
• The lawsuit alleges a scheme involving the unauthorized transfer and sale of approximately 96 million Datavault AI, Inc. (DVLT) common shares that were pledged as collateral in a stock loan transaction.
• Scilex entered a stock loan agreement with St. James Bank in late 2025, pledging DVLT shares as collateral, which were not authorized for sale under contractual conditions.
• The Wade Defendants allegedly transferred these shares into brokerage accounts at BNY Mellon and systematically sold them into the public market without authorization, using the proceeds to fund the loan and generate profits.
• St. James Bank allegedly made false representations to Scilex that the pledged shares had not been transferred or sold.
• The large volume of trading activity involving the Pledged DVLT Shares allegedly significantly impacted the market price of DVLT shares, causing substantial financial harm to Scilex.
• Scilex is seeking recovery of the 96 million Pledged DVLT shares or their full value, compensatory damages exceeding $100 million, punitive damages, disgorgement of profits, attorneys' fees and costs, and other relief.
• The complaint asserts claims for federal securities fraud, state securities fraud (against Wade Defendants), fraudulent inducement (against Wade Defendants), unlawful conversion (against all defendants), and negligence (against BNY Mellon).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development due to the alleged misappropriation of substantial collateral assets and the initiation of a major lawsuit, which introduces financial uncertainty and legal costs.

Positives

• Scilex is proactively pursuing legal action to recover misappropriated assets and damages.
• The company is seeking substantial compensatory and punitive damages, which, if successful, could significantly benefit its financial position.

Negatives

• Approximately 96 million Datavault AI, Inc. shares, pledged as collateral, were allegedly misappropriated and sold without authorization.
• The alleged unauthorized sale of shares caused substantial financial harm to Scilex and impacted the market price of DVLT shares.
• The company is involved in significant litigation, which can be costly and time-consuming, with an uncertain outcome.
• The alleged actions by the defendants represent a breach of trust and contractual obligations.

Risks

• Uncertainty regarding Scilex's ability to recover the pledged securities or obtain compensatory/punitive damages.
• General economic, political, and business conditions could impact the lawsuit's outcome or the value of any recovered assets.
• Risks related to the development and successful marketing of Scilex's products, and the ability to grow profitably and retain its key employees.
• Potential product candidates may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.
• Uncertainty regarding the regulatory pathway for Scilex's product candidates.
• Scilex's product candidates may not be beneficial to patients or successfully commercialized.
• Risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies, and the willingness of physicians to prescribe these therapies.
• Risks that the prior results of clinical trials may not be replicated.
• Regulatory and intellectual property risks.

Future Outlook

Scilex intends to pursue all available remedies to recover the misappropriated securities and hold the responsible parties accountable. The company acknowledges risks and uncertainties regarding its ability to recover the pledged securities, obtain compensatory or punitive damages, or disgorge profits in connection with the lawsuit.

Management Comments

• "As the Complaint alleges, this is an egregious conspiracy to defraud Scilex out of tens of millions of dollars worth of securities."
• "By this action, Scilex intends to hold the Wade Defendants responsible for the full extent of their alleged illegal activities, as well as BNY Mellon for allegedly opening and administering brokerage accounts through which the securities were sold without Scilex's authorization."

Industry Context

StockSavvy.ai notes that this lawsuit highlights critical issues in collateral management and the potential for fraud within financial transactions, particularly involving pledged securities. Such incidents, while not common, underscore the importance of robust due diligence and oversight in lending and brokerage operations. The involvement of a major financial institution like BNY Mellon, even if alleged to be negligent, could prompt broader scrutiny of custodial practices in the industry.

Legal Proceedings

• Scilex Holding Company filed a complaint against Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd., and The Bank of New York Mellon Corporation (BNY Mellon) in the United States District Court for the Central District of California.
• The complaint alleges federal securities fraud, state securities fraud (against Wade Defendants), fraudulent inducement (against Wade Defendants), unlawful conversion (against all defendants), and negligence (against BNY Mellon).
• Scilex is seeking recovery of approximately 96 million misappropriated Datavault AI, Inc. common shares, compensatory damages exceeding $100 million, punitive damages, disgorgement of profits, attorneys' fees and costs, and other relief.

Stakeholder Impact

• Shareholders: Potential for significant financial recovery if the lawsuit is successful, but also exposure to legal costs and uncertainty regarding the outcome. The alleged misappropriation of assets represents a direct loss to the company's value.
• Creditors: The outcome of the lawsuit could impact the company's financial health and ability to meet obligations, depending on the recovery of assets and damages.
• Management: Significant time and resources will be dedicated to managing the litigation.

Next Steps

• Scilex will pursue all available remedies to recover the misappropriated securities and hold the responsible parties accountable through the ongoing lawsuit.
• The legal proceedings will continue in the United States District Court for the Central District of California.

Key Dates

Recommendation

The filing details a significant alleged fraud involving the misappropriation of 96 million shares pledged as collateral, leading to a lawsuit seeking over $100 million in damages. This introduces substantial financial uncertainty, potential losses, and considerable legal costs. While the company is pursuing recovery, the outcome is uncertain and the immediate impact is highly negative, suggesting a 'sell' recommendation for investors to mitigate risk until there is greater clarity on the resolution of this material legal challenge.

Keywords

Scilex Holding Company, SCLX, securities fraud, lawsuit, collateral, Datavault AI, DVLT, stock loan, BNY Mellon, fraudulent inducement, unlawful conversion, negligence, non-opioid pain management, pharmaceuticals, litigation, corporate governance